Treatment of speech anxiety with alpha-7 nicotinic acetylcholine receptor agonists

JP2023553354A5Inactive Publication Date: 2024-12-03VANDA PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532250
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-09
Filing Date
2021-11-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for social anxiety disorder (SAD) and its performance-limited subtype (SAD-PO), such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, have slow onset of action, high rates of partial responses, and adverse effects, failing to effectively address the significant distress experienced by many patients during infrequent events like public speaking.

Method used

Administration of the potent and selective α7 nicotinic acetylcholine receptor (α7nAChR) agonist, (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, or its pharmaceutically acceptable salts, to treat or prevent symptoms of speech anxiety and SAD-PO, including public speaking anxiety, through various routes of administration.

Benefits of technology

The compound effectively reduces the severity and frequency of anxiety symptoms, including physiological, cognitive, and emotional manifestations, providing rapid relief and preventing anxiety onset in situations likely to provoke these symptoms.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are methods for treating or preventing speech anxiety (PSA), which may be present as a symptom of social anxiety disorder (SAD), including the performance-limited (SAD-PO) subtype of SAD. The method of treatment comprises administering to a subject a therapeutically effective dose of an α7 nAChR agonist, such as (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to Related Applications This patent application claims priority to U.S. Provisional Patent Application No. 63 / 118,121, filed on November 25, 2020; U.S. Provisional Patent Application No. 63 / 118,132, filed on November 25, 2020; and U.S. Provisional Patent Application No. 63 / 158,449, filed on March 9, 2021.

[0002] The present invention relates to a method of treating speech - related anxiety (PSA) that includes public - speaking anxiety as a primary symptom of, or related to, social anxiety disorder (SAD) or social anxiety disorder - performance - limited subtype (SAD - PO). The present invention particularly relates to a method of treating anxiety related to speech or performance as described herein using an alpha7 nicotinic acetylcholine receptor (α7nAChR) agonist, particularly (R)-3-(6 - p - tolyl - pyridin - 3 - yloxy)-1 - azabicyclo[2.2.2]octane.

Background Art

[0003] Speech - related anxiety (PSA), also known as fear of speech or fear of speaking in public, is classified as social anxiety disorder (SAD) in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM - 5) (2013) of the American Psychiatric Association. The prevalence of PSA is reported to be as high as 15% - 30% in the general population, and up to 10% of those with PSA report that this condition interferes with daily activities including work and education. (Vickram Tejwani, MD, et al., Public Speaking Anxiety in Graduate Medical Education - A Matter of Interpersonal and Communication Skills?, Journal of Graduate Medical Education, p. 111 (Feb. 01, 2016).)

[0004] Social anxiety disorder (SAD), including PSA, is characterized by excessive fear, discomfort, and self-consciousness in a variety of social situations, including performing and giving speeches in front of others. SAD is a chronic condition that typically begins in late childhood and early adolescence and is often associated with the development of comorbid mental health problems such as major depression and substance use disorders. SAD is a multifactorial disorder with both environmental and genetic factors, as well as their interactions. Generalized SAD is a particularly severe form of SAD, involving fear of any social situation. Social anxiety disorder performance-specific (SAD-PO) is a specific type of SAD based on DSM-5 criteria. This particular type of SAD is typically not associated with comorbid psychiatric conditions or innate behavioral inhibition and usually has a later onset. SAD-PO occurs in a narrower context, namely when the affected person has to perform in public. PSA and its symptoms may occur in individuals who meet the diagnostic criteria for SAD, SAD-PO, both SAD and SAD-PO, or neither SAD nor SAD-PO.

[0005] The Speech Anxiety Scale (PSAS) is used to assess the three-component model of anxiety. The PSAS consists of 17 items across three subscales: 1) Cognitive (8 items), 2) Behavioral (4 items), and 3) Physiological (5 items). Each item has a score ranging from 1 ("not at all") to 5 ("very much"), and five items are decoded on the scale. The total PSAS score can range from 17 to 85 and is considered a reliable and comprehensive measure for assessing speech anxiety.

[0006] Symptoms of PSA, SAD, and SAD-PO may include physiological biomarkers associated with acute stress responses, such as an increased heart rate, increased blood pressure, increased body temperature, or increased sweating, as well as other physical, cognitive, and emotional symptoms, such as tremors or shaking, flushing, rapid breathing or shortness of breath, dizziness, nausea, restlessness, muscle tension, sleep disturbances, excessive rumination or worry, inability to concentrate on anything other than the source of anxiety, a feeling of emptiness, fear of judgment, fear of failure, fear of embarrassment, fear of people looking at the person, fear of specific situations, such as fear of ordering in a restaurant or speaking in front of a crowd, engaging in negative self-talk, and other symptoms known in the art. Emotional, cognitive, and physical symptoms often lead individuals suffering from such anxiety to change their behavior, including refusing invitations, clinging to close people in group situations, and avoiding situations, events, or circumstances that trigger anxiety. Symptoms can often manifest as a fear of speaking or interacting in situations where the individual must be in front of others. Individuals with PSA, SAD, and SAD-PO may also be at risk of developing unhealthy coping mechanisms, including the use of drugs and alcohol as means of relaxation in anxiety-inducing situations.

[0007] Current treatments for SAD and SAD-PO include psychotherapy, pharmacology, and combinations thereof. Selective serotonin reuptake inhibitors (SSRIs), paroxetine, sertraline, and fluvoxamine, as well as the serotonin-norepinephrine reuptake inhibitor (SNRI), venlafaxine, are approved by the FDA for SAD in the United States. Other medications, including monoamine oxidase inhibitors (MAOIs) and benzodiazepines (BZDs), have shown efficacy in placebo-controlled clinical trials with small sample sizes. SSRIs increase serotonin levels in synapses and are considered a first-line treatment for SAD, but their onset of action is slow. Furthermore, approximately 40% of patients treated with SSRIs report sexual dysfunction associated with SSRI use. BZDs are gamma-aminobutyric acid (GABA)-positive allosteric modulators with adverse effects such as drowsiness, memory impairment, sedation, and abuse potential. In addition, a high rate of partial response and a low rate of long-term remission remain.

[0008] Many patients with SAD, including SAD-PO, experience significant distress only during infrequent events (e.g., speech or social gatherings) or only partially benefit from psychotherapy and pharmacology. Therefore, there is an unmet medical need for more effective anxiolytics with improved safety profiles, including those that can be used as needed, such as for the treatment of speech or performance anxiety in patients with or without a diagnosis of SAD or SAD-PO.

[0009] Alpha-7 nicotinic acetylcholine receptors (α7-nAChRs) are ligand-opening ion channels involved in many physiological and pathological processes. A unique characteristic of α7-nAChRs is their high Ca 2+ It exhibits permeability and rapid desensitization. α7-nAChR is highly expressed in the nervous system, particularly in areas involved in cognition and memory, and its dysfunction is associated with several neuropsychiatric and neurological disorders, including schizophrenia and Alzheimer's disease (AD).

[0010] The following compound (R)-3-(6-p-tolylpyridine-3-yloxy)-1-aza-bicyclo[2.2.2]octane:

[0011] [ka]

[0012] This compound is a potent and selective α7nAChR agonist, disclosed in U.S. Patent No. 7,579,362. This compound is also known as (R)-3-((6-(p-tolyl)pyridine-3-yl)oxy)quinuclidine, AQW-051, VQW-765, and by IUPAC name (3R)-3-{[6-(4-methylphenyl)pyridine-3-yl]oxy}-1-azabicyclo[2.2.2]octane. VQW-765 has a molecular weight of 294.39 g / mol, a pKa (predicted value) of 9.09 ± 0.33, and a LogP (predicted value) of 3.447 ± 0.402. A pharmaceutically acceptable acid addition salt of (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane, particularly a monofumarate, is disclosed in U.S. Patent No. 9,365,565.

[0013] U.S. Patent No. 7,579,362 describes VQW-765 as an α7nAChR agonist useful for the prevention and treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety disorders, as well as neurodegenerative disorders such as senile dementia and Alzheimer's disease, and other intellectual disorders such as attention deficit hyperactivity disorder (ADHD); Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, seizures, Tourette syndrome, OCD (obsessive-compulsive disorder), neurological disorders, postoperative and inflammatory pain, phantom limb pain, cognition, smoking cessation, memory impairment and functional impairment, learning disabilities, panic disorder, narcolepsy, nociception, AIDS dementia, senile dementia, autism, tardive dyskinesia, social phobia, and pseudodementia. [Overview of the Initiative]

[0014] A first aspect of this disclosure provides a method for treating a subject suffering from speech anxiety or a symptom thereof, comprising administering to the subject (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof in a dose effective for treating speech anxiety or a symptom thereof. In certain embodiments, the subject may suffer from speech anxiety as a primary symptom of social anxiety disorder (SAD) or SAD-PO (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0015] A second aspect of this disclosure provides a method for treating social anxiety disorder (SAD) or its symptoms in a subject, comprising administering to the subject (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof in a dose effective for treating SAD or its symptoms. In certain embodiments, the subject may have social anxiety disorder-performance-limited subtype (SAD-PO) and may or may not have been diagnosed with SAD or SAD-PO.

[0016] A third aspect of this disclosure provides a method for preventing the manifestation of one or more symptoms of speech anxiety in a subject. According to this aspect, the method may include administering a compound to a subject before engaging in a situation that is likely to induce or cause anxiety or one or more symptoms of anxiety, such as a speech or public performance. The compound may be (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, and may be administered in a dose effective in preventing such manifestation.

[0017] A fourth aspect of this disclosure provides a compound which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof for use in the treatment of speech anxiety or its symptoms. In various embodiments, the subject may have speech anxiety as a primary symptom of social anxiety disorder (SAD) or SAD-PO (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0018] A fifth aspect of this disclosure provides a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in the treatment of social anxiety disorder (SAD) or its symptoms. Subjects may, in certain embodiments, have social anxiety disorder-performance-limited subtype (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0019] A sixth aspect of this disclosure provides a pharmaceutical composition comprising a compound which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in the treatment of speech anxiety or its symptoms. In various embodiments, subjects may have speech anxiety as a primary symptom of social anxiety disorder (SAD) or SAD-PO (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0020] A seventh aspect of this disclosure provides a pharmaceutical composition, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in the treatment of social anxiety disorder or its symptoms. Subjects may, in certain embodiments, have social anxiety disorder-performance-limited subtype (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0021] An eighth aspect of this disclosure provides a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in the manufacture of a pharmaceutical composition comprising a compound for use in the treatment of speech anxiety. In various embodiments, the subject may have speech anxiety as a primary symptom of social anxiety disorder (SAD) or SAD-PO (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0022] A ninth aspect of this disclosure provides a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in the manufacture of a pharmaceutical composition comprising a compound for use in the treatment of social anxiety disorder (SAD). Subjects may, in certain embodiments, have social anxiety disorder-performance-limited subtype (SAD-PO), and may or may not have been diagnosed with SAD or SAD-PO.

[0023] These and other aspects, advantages and notable features of the present invention will become apparent from the following detailed description which provides a more detailed explanation of various embodiments of the present invention. [Modes for carrying out the invention]

[0024] In various embodiments of the present invention, the methods described herein include methods for treating subjects suffering from speech anxiety, subjects suffering from social anxiety disorder (SAD) or at least one of its symptoms, or subjects suffering from a performance-limited subtype of social anxiety disorder (SAD-PO). Such subjects may experience performance anxiety or speech anxiety as their primary symptom.

[0025] As used herein, references to subjects suffering from social anxiety disorder may be considered to include subjects meeting the diagnostic criteria for social anxiety disorder (SAD) as understood by one of ordinary skill in the art. For example, such subjects may meet the diagnostic criteria for social anxiety disorder set forth on pages 202-208 (2013) of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) of the American Psychiatric Association. Such references are considered to include both subjects diagnosed with SAD and subjects who may meet the diagnostic criteria but who have not been diagnosed for any of a number of reasons, including, for example, not having been presented for clinical care for SAD or its symptoms.

[0026] References to subjects suffering from social anxiety disorder - performance only (SAD-PO) may be considered to include subjects meeting the diagnostic criteria for the SAD-PO subtype as understood by one of ordinary skill in the art. For example, such subjects may meet the diagnostic criteria for the specific factors of social anxiety disorder - performance only as set forth in the DSM-5. Such references are considered to include both subjects diagnosed with SAD-PO and subjects who may meet the diagnostic criteria but who have not been diagnosed for any of a number of reasons, including, for example, not having been presented for clinical care for SAD-PO or its symptoms.

[0027] References to subjects suffering from speech anxiety (PSA, also known as fear of speech or fear of speaking in public) can include subjects experiencing symptoms of anxiety related to speech or performance. Such anxiety, which may be called "stage fright," can be caused by any of several types of public performance, such as musical performance, sports performance, acting performance, and speech, or by anticipation of such public performance. Such subjects may meet many or all of the diagnostic criteria for SAD, including, for example, significant anxiety or fear about performing in front of others (e.g., giving a speech). Subjects suffering from PSA can include those who have not been diagnosed with SAD but who are nevertheless experiencing PSA. For example, under DSM-5, a subject who fears speaking in public will not receive a diagnosis of social anxiety disorder if this activity does not routinely occur in the subject's job or in work in the classroom and the subject does not experience significant distress about it. Nevertheless, such subjects may be considered to have PSA and to benefit from the treatments described herein. Such subjects can be further identified, for example, by objective measures such as the Speech Anxiety Scale (PSAS), where a score of 60 or above is consistent with identification of the subject as having substantial speech anxiety.

[0028] As used herein, references to the treatment of a subject using one or more of PSA, SAD, or SAD-PO can be considered to include a reduction in the severity of the subject's symptoms, prevention or attenuation of the progression of PSA, SAD, or SAD-PO in the subject, prevention or attenuation of the subject's symptoms in response to a situation or stimulus, or complete resolution of one or more of the subject's symptoms of PSA, SAD, or SAD-PO after such one or more symptoms have manifested in the subject.

[0029] In one embodiment, a method is provided for treating a subject suffering from PSA, SAD, SAD-PO, or any one or more of the aforementioned conditions. Such a subject may or may not be formally diagnosed with any of the aforementioned conditions. In particular, this may include a subject suffering from speech anxiety or public performance anxiety. In this embodiment, the method comprises the process of administering a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, to the subject in an amount, i.e., dose, effective to produce a desired therapeutic response. In certain embodiments, the compound may be {2-(R)-3-[[6-(4-methylphenyl)-3-pyridinyl]oxy]-1-azabicyclo[2.2.2]octane fumarate.

[0030] In subjects having PSA, SAD, or SAD-PO, or in methods described herein for treating the manifestation or symptoms thereof in such subjects, the effective dose for producing a desired therapeutic response is the amount or dosage effective for treating the symptoms or underlying PSA, SAD, or SAD-PO in the subject, for shortening the course of the symptoms of the condition or disorder, for reducing the severity of its manifestation, or for preventing, alleviating, or improving the symptoms of the condition or disorder. Human doses may range from approximately 0.5 mg to approximately 700 mg, as shown in Table 1, for example, approximately 0.5 mg, approximately 2 mg, approximately 2.5 mg, approximately 10 mg, approximately 15 mg, approximately 75 mg, approximately 100 mg, approximately 200 mg, or approximately 700 mg.

[0031] Table 1: Daily dose:

[0032] [Table 1]

[0033] The dosage of the active agent of the present invention can be modified to administer an amount of the active agent effective in achieving a desired therapeutic response to a particular subject without being toxic to the subject. The selected dosage depends on various pharmacokinetic factors, including the route of administration, time of administration, rate of excretion, duration of treatment, other drugs, compounds or materials used in combination with the specific composition used, the age, sex, weight, condition, overall health and medical history of the subject being treated, and similar factors well known in the medical field.

[0034] In another embodiment, a method is provided for treating PSA, SAD, SAD-PO, or at least one of the symptoms thereof in a subject by administering a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, to the subject. The compound may be administered in doses as described herein as therapeutically effective.

[0035] In another embodiment, a therapeutic method is provided comprising administering a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, to a human subject suffering from PSA, SAD, or SAD-PO, or any one of the aforementioned symptoms. In various embodiments, the subject may or may not be formally diagnosed with SAD or SAD-PO. In such a method, the compound is administered in a therapeutically effective dose, i.e., a dose sufficient to alleviate at least one symptom of SAD or SAD-PO. Such symptoms of PSA, SAD, and SAD-PO may include physical, cognitive, and emotional symptoms, such as tremors or shaking, flushing, increased heart rate, increased blood pressure, increased body temperature, or increased sweating, rapid breathing or difficulty breathing, dizziness, nausea, restlessness, muscle tension, sleep disturbances, excessive rumination or worry, inability to concentrate on anything other than the source of anxiety, a feeling of emptiness in the affected person, fear of judgment, fear of failure, fear of embarrassment, fear of people looking at the affected person, fear of specific situations, such as fear of ordering in a restaurant or speaking in front of a crowd, engaging in negative self-talk, and other symptoms known in the art. Emotional, cognitive, and physical symptoms may also include behavioral changes, such as refusing to solicit, clinging to close people in group situations, and avoiding situations, events, or circumstances that cause anxiety, as well as unhealthy coping mechanisms, such as the use of alcohol or drugs.

[0036] Further embodiments provide methods for preventing the acute onset of one or more symptoms of PSA, SAD, or SAD-PO in a subject. Prevention as defined herein may include overall or partial prevention, such as a reduction in severity. In such embodiments, the method involves administering a compound, which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, to a subject before engaging in an anxiety-prone situation, for example, before participating in public speaking, and in an amount effective to prevent the symptom(s). In various embodiments, situations that may trigger anxiety may be, for example, performing or speaking in front of one or more other people, and symptoms of SAD or SAD-PO whose manifestation should be prevented may be, for example, tremors or shaking, flushing, increased heart rate, rapid breathing or difficulty breathing, dizziness, nausea, restlessness, sweating, muscle tension, sleep disturbances, excessive rumination or worrying, inability to concentrate on anything other than the source of anxiety, a feeling of emptiness in the person suffering, fear of judgment, fear of failure, fear of embarrassment, fear of people looking at the person suffering, fear of certain situations, such as fear of ordering in a restaurant or speaking in front of a crowd, and engaging in negative self-talk.

[0037] In any of the methods described herein, the compound may be (R)-3-(6-p-tolylpyridine-3-yloxy)-1-aza-bicyclo[2.2.2]octane in either its free base form or its pharmaceutically acceptable acid addition salt form. As used herein, a pharmaceutically acceptable salt means a salt in its free form that is not toxic, not biologically unacceptable, or otherwise biologically undesirable. A preferred pharmaceutically acceptable salt is one that is pharmacologically effective and suitable for contact with the target tissue without excessive toxicity, irritation, or allergic reaction. Particularly preferred pharmaceutically acceptable acid addition salts of the compound are described in U.S. Patent No. 9,365,565 and include the forms of fumarate, maleate, chloride, phosphate, succinate, or malonic acid acid addition salts. In particular, the compound may be (R)-3-(6-p-tolylpyridin-3-yloxy)-1-azabicyclo[2.2.2]octane in the form of a monofumarate addition salt, i.e., {2-(R)-3-[[6-(4-methylphenyl)-3-pyridinyl]oxy]-1-azabicyclo[2.2.2]octane fumarate.

[0038] The compounds of the present invention can be administered by one or more routes of administration using one or more of the various methods known in the art. As will be understood by those skilled in the art, the route and mode of administration vary depending on the desired outcome. Routes of administration may include, for example, intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral administration routes by injection or infusion. As used herein, the term “parenteral administration” usually means modes of administration other than enteral and topical administration by injection, and includes, but is not limited to, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intratracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injections and infusions. Alternatively, the compositions can be administered by parenteral routes, such as topical, epidermal, or mucosal administration routes, such as intranasal, oral, vaginal, rectal, sublingual, or topical.

[0039] The active compound can be prepared as a solid immediate-release form comprising the compound and one or more pharmaceutically acceptable excipients. Alternatively, the active compound can be prepared using a controlled-release formulation comprising a carrier that protects the compound from rapid release, such as an implant, a transdermal patch, and a microencapsulation delivery system. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Many methods for preparing such formulations are patented or generally known to those skilled in the art.

[0040] Preferred therapeutic compositions are those for oral or transdermal administration. Compositions for enteral or parenteral administration are, for example, unit dosage forms such as sugar-coated tablets, tablets, capsules, suppositories, and ampoules. The unit content of the active ingredient in each dose does not need to constitute a therapeutically effective dose itself, as such an amount can be reached by administering multiple dose units. Compositions according to the present invention may contain, for example, about 10% to about 100%, preferably about 20% to about 60%, of the active ingredient.

[0041] Unless otherwise specified, the pharmaceutical compositions according to the present invention are prepared in a manner known to the present, for example, by conventional mixing, granulation, sugar coating, dissolution, or freeze-drying processes. When preparing compositions for oral dosage forms, any of the usual pharmaceutical media, such as water, glycol, oil, alcohol, carriers, such as starch, sugar, or microcrystalline cellulose, diluents, granulators, lubricants, binders, or disintegrants, can be used. For ease of administration, tablets and capsules represent the most advantageous oral drug unit forms, in which case solid pharmaceutical carriers are obviously used.

[0042] In particular, the compound may be administered orally in a solid immediate-release form, such as a tablet or capsule containing VQW-765 in amounts of approximately 0.5 mg, 2 mg, 2.5 mg, 10 mg, 15 mg, 75 mg, 100 mg, 200 mg, or 700 mg of the compound, together with one or more pharmaceutically acceptable excipients.

[0043] Alternatively, the compound may be administered orally in a controlled-release solid form comprising the compound and one or more pharmaceutically acceptable excipients. The controlled-release form may contain a higher dose with lower bioavailability compared to the immediate-release form. In further embodiments, the compound may be administered orally in a liquid suspension form, or intravenously in a liquid suspension form at a daily dose that provides exposure comparable to the compound.

[0044] In another embodiment, a compound is provided which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof for use in any of the therapeutic methods described herein.

[0045] In another embodiment, a pharmaceutical composition is provided comprising a compound which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.

[0046] In another embodiment, a compound is provided which is (R)-3-(6-p-tolylpyridine-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition comprising the compound for use in any of the methods described herein.

[0047] Those skilled in the art will understand that additional embodiments can be selected by combining the above embodiments or by referring to the examples shown herein.

[0048] Example 1: Social Anxiety Disorder with Performance-Limited Type (SAD-PO); Single Dose A multicenter, randomized, double-blind, placebo-controlled trial will be conducted to evaluate the efficacy and safety of VQW-765 in patients with substantial speech anxiety, according to the design in Table 2. In this study, 220 patients will be randomized in a 1:1 ratio to one of two arms. Patients in one arm will be administered a capsule containing 10 mg of VQW-765 ({2-(R)-3-[[6-(4-methylphenyl)-3-pyridinyl]oxy]-1-azabicyclo[2.2.2]octane fumarate), and patients in the other arm will be administered a placebo. The VQW-765 capsule is a white, opaque, hard gelatin capsule, size 3, and is supplied at a strength of 10 mg, also containing lactose monohydrate, microcrystalline cellulose, methocel, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Placebo capsules are supplied in the same size and appearance as those containing VQW-765.

[0049] Table 2: Clinical trial design

[0050] [Table 2]

[0051] During the screening phase (Table 2, Visit 1), the Speech Anxiety Scale (PSAS) is used to identify patients with substantial speech anxiety, defined as having a PSAS score of 60 or higher. Clinical and laboratory assessments are performed to determine each patient's eligibility. Eligible patients are trained in using the Self-Rated Subjective Unit Distress Scale (SUDS). In addition, the Liebowitz Social Anxiety Score (LSAS) is administered, and blood samples are taken for pharmacogenetic analysis. The LSAS is a clinician-administered scoring scale used to assess how social anxiety plays a role in daily life across various situations. The LSAS is used to study outcomes in clinical trials and includes 24 items to assess both social anxiety in situations and avoidance of those situations. Each item is scored as follows: 0, none; 1, mild; 2, moderate; or 3, severe. The maximum score is 144.

[0052] During the treatment phase (Table 2, Visit 2), eligible patients will be randomized to take a modified Trier Social Stress Test (TSST), which includes a speech task, approximately two hours after administration of the study drug. Prior to randomization, patients will be asked to provide baseline SUDS scores.

[0053] Patients are given a single dose of either a 10 mg VQW-765 or placebo capsule. Two hours later, patients are instructed to prepare a 5-minute speech for a job interview and are asked to provide a SUDS score (pause phase). The patient then has 3 minutes to mentally prepare. SUDS scores are collected every minute (prediction phase). Next, the patient, dressed in a white coat, delivers a 5-minute speech to an audience of two clinical staff members who were previously unknown to the patient. SUDS scores are collected immediately before the speech and then every minute during the speech (performance phase). The speech is video recorded, and the video camera is observed by the patient. If the patient stops 5 minutes early and remains quiet for approximately 20 seconds, the primary clinical staff member says, "You still have time." If the patient does not continue, the clinical staff member begins questioning until the performance phase is complete. Physiological biomarkers related to anxiety or acute stress response, including heart rate, blood pressure, body temperature, and sweating, are continuously monitored by medical devices throughout the speech task.

[0054] After the TSST debriefing, the biomarker measurement device is removed, and the clinician general impression-change (CGI-C) and patient general impression-change (PGI-C) are performed. Subsequently, vital signs, safety laboratory, pharmacokinetic (PK) samples are collected, and electrocardiograms (ECGs) are recorded.

[0055] The efficacy of a single oral dose of 10 mg of VQW-765 will be evaluated compared to placebo in terms of changes in anxiety scores, measured by changes in SUDS; CGI-C scale; PGI-C scale; and changes in anxiety biomarkers during the TSST, from baseline to the performance phase during the TSST. Furthermore, the safety and tolerability of a single oral dose of 10 mg of VQW-765, as well as pharmacogenetic evaluations to identify genetic factors associated with clinical phenotype and treatment response, will be assessed. A total of 10 SUDS scores will be collected during the TSST: one at task introduction, three during the prediction phase, and six during the performance phase. Based on a two-sided t-test at a 5% significance level, the planned sample size of 110 patients per arm (220 patients total) provides approximately 85% power to detect a mean difference of 12 points in the mean SUDS score, assuming a standard deviation of 28 in each treatment group.

[0056] While various embodiments are described herein, it will be understood from this specification that various combinations of elements, modifications, or improvements may be made by those skilled in the art and remain within the scope of the invention. Furthermore, many modifications can be made to adapt the teachings of the invention to specific situations or materials without departing from the essential scope of the invention. Thus, the invention is not limited to the specific embodiments disclosed, and the invention is intended to include all embodiments that fall within the scope of the appended claims.

Claims

1. A pharmaceutical composition for treating or preventing the onset of public speaking anxiety or a symptom thereof in a subject, comprising a compound which is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a pharma- ceutically acceptable salt thereof, in a dose effective for treating or preventing the onset of public speaking anxiety or a symptom thereof.

2. The method of claim 1, wherein the subject suffers from speech anxiety as a primary symptom of social anxiety disorder (SAD).

3. The method of claim 2, wherein the subject has been diagnosed with SAD.

4. The pharmaceutical composition according to claim 2, wherein the subject suffers from speech anxiety as a primary symptom of SAD-performance-limited type (SAD-PO).

5. The method of claim 1 , wherein the symptoms are physically manifested in the subject.

6. The pharmaceutical composition of claim 5, wherein the symptoms are selected from the group consisting of tremors, tremors, flushing, increased heart rate, increased blood pressure, increased body temperature, rapid breathing, difficulty breathing, dizziness, nausea, restlessness, increased sweating, muscle tension, and sleep disorders.

7. The method of claim 1 , wherein the symptoms are cognitively or emotionally manifested in the subject.

8. 8. The pharmaceutical composition of claim 7, wherein the symptoms are selected from the group consisting of excessive rumination or worry, an inability to concentrate on anything other than what is causing the anxiety, a feeling that the sufferer's mind is empty, fear of judgment, fear of failure, fear of embarrassment, fear of people seeing the sufferer, fear of certain situations, and engaging in negative self-talk.

9. The pharmaceutical composition of claim 1, wherein the dose is from 0.007 mg / kg to 10 mg / kg.

10. 2. The method of claim 1, wherein the dose is 0.5 mg, 2 mg, 2.5 mg, 10 mg, 15 mg, 75 mg, 100 mg, 200 mg or 700 mg.

11. The pharmaceutical composition of claim 10, wherein the dose is 10 mg.

12. The method of claim 1, wherein the compound is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in the mono-fumaric acid addition salt form.

13. The method of any one of claims 1 to 12, wherein the compound is in a solid immediate release form for oral administration comprising the compound and one or more pharma- ceutically acceptable excipients.

14. The medicament according to any one of claims 1 to 12, wherein the compound is in a solid controlled release form for oral administration comprising the compound and one or more pharma- ceutically acceptable excipients.

15. The method of any one of claims 1 to 11, wherein the compound is in the form of a liquid suspension for oral administration.

16. Use of a compound which is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament comprising said compound for treating or preventing the onset of speech anxiety or symptoms thereof in a subject.

17. 17. The use according to claim 16, wherein the subject suffers from speech anxiety as a presenting symptom of social anxiety disorder (SAD).

18. The use according to claim 17, wherein the subject suffers from speech anxiety as a presenting symptom of SAD-performance-limited type (SAD-PO).

19. The use of claim 16, wherein the symptoms are physically manifested in the subject.

20. 20. The use of claim 19, wherein the symptoms are selected from the group consisting of shaking, tremors, flushing, increased heart rate, increased blood pressure, increased body temperature, rapid breathing, difficulty breathing, dizziness, nausea, restlessness, increased sweating, muscle tension, and sleep disorders.

21. 17. The use of claim 16, wherein the symptoms are cognitive or emotionally manifest in the subject.

22. 22. The use of claim 21, wherein the symptoms are selected from the group consisting of excessive rumination or worry, an inability to concentrate on anything other than what is causing the anxiety, a feeling that the sufferer's mind is empty, fear of judgement, fear of failure, fear of embarrassment, fear of people seeing the sufferer, fear of certain situations, and engaging in negative self-talk.

23. The use of claim 16, wherein the medicament comprises 0.5 mg, 2 mg, 2.5 mg, 10 mg, 15 mg, 75 mg, 100 mg, 200 mg or 700 mg of the compound.

24. The use of claim 23, wherein the medicament comprises 10 mg of the compound.

25. The use according to claim 16, wherein the compound is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in the mono-fumaric acid addition salt form.

26. The use of any one of claims 16 to 25, wherein the compound is a solid immediate release form comprising the compound and one or more pharma- ceutically acceptable excipients for oral administration.

27. The use of any one of claims 16 to 25, wherein the compound is a solid controlled release form comprising the compound and one or more pharma- ceutically acceptable excipients for oral administration.

28. The use according to any one of claims 16 to 25, wherein the compound is in the form of a liquid suspension for oral administration.